Arrowstreet Capital Limited Partnership Raises Stake in Natera, Inc. (NASDAQ:NTRA)

Arrowstreet Capital Limited Partnership increased its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 874.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 296,372 shares of the medical research company's stock after acquiring an additional 265,948 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 0.22% of Natera worth $46,916,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Blue Trust Inc. increased its holdings in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc grew its holdings in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after purchasing an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares during the last quarter. Principal Securities Inc. raised its stake in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its position in Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Remove Ads

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 663 shares of the company's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the transaction, the insider now directly owns 156,044 shares in the company, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the sale, the chief executive officer now directly owns 203,354 shares in the company, valued at $29,160,963.60. The trade was a 30.03 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 325,922 shares of company stock worth $51,603,664. 7.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

NTRA has been the topic of several research reports. StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a research report on Wednesday, March 19th. Guggenheim raised their price target on Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research report on Friday, January 17th. Morgan Stanley upped their price objective on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. BTIG Research reiterated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Finally, Piper Sandler increased their price target on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $178.12.

Natera Trading Down 3.5 %

NASDAQ:NTRA traded down $4.84 during midday trading on Friday, reaching $133.87. 3,247,142 shares of the stock traded hands, compared to its average volume of 1,377,854. The stock has a market capitalization of $18.10 billion, a P/E ratio of -76.06 and a beta of 1.80. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a fifty day moving average of $156.81 and a 200 day moving average of $151.57.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.